Open an account

Stevanato Group SpA

STVN · NYSE

$19.01−$0.01 (−0.05%)TodayMarket closed ·
Prev close $19.02

About STVN

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 6,010 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Employees
6,010
Headquarters
Piombino Dese, Padova
Listed
Jul 16, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services
Website
stevanatogroup.com

STVN key statistics

Market cap
5.19B
Price-earnings ratio
34.77
Dividend yield
0.32%
Average volume
308.47K
Volume
261.86K
Open price
$18.88
High today
$19.07
Low today
$18.76
52 Week high
$27.99
52 Week low
$12.89

Stevanato Group SpA (STVN) at a glance

Stevanato Group SpA (STVN) last traded at $19.01, with a market cap of 5.19B, a price-to-earnings ratio of 34.77 and a dividend yield of 0.32%.

Today the stock has traded between $18.76 and $19.07. The current price is 1.3% above the day's low and 0.3% below its high.

Volume so far is 261.86K shares, in line with the average of 308.47K shares a day.

Over the past year Stevanato Group SpA has ranged from $12.89 to $27.99, and now sits 41% of the way up that range.

Stevanato Group SpA met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.14 per share against an estimate of $0.1301.

The average analyst price target is $25.90, 36.3% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

67%of 6 analyst ratings say Buy
  • Buy66.7%
  • Hold33.3%
  • Sell0.0%
Price target · 13 analystsAvg $25.90
Low
$20.20
Now
$19.01
High
$33.60

STVN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 6.0% on average.

  1. Q3 FY24: reported $0.12 per share against an estimate of $0.13
  2. Q4 FY24: reported $0.19 per share against an estimate of $0.1879
  3. Q1 FY25: reported $0.10 per share against an estimate of $0.0907
  4. Q2 FY25: reported $0.11 per share against an estimate of $0.1071
  5. Q3 FY25: reported $0.14 per share against an estimate of $0.1265
  6. Q4 FY25: reported $0.18 per share against an estimate of $0.1725
  7. Q1 FY26: reported $0.11 per share against an estimate of $0.1047
  8. Q2 FY26: reported $0.14 per share against an estimate of $0.1301

STVN news

  • Press releaseBusiness Wire

    Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026

  • Press releaseBusiness Wire

    Stevanato Group to Participate in Two Upcoming Investor Conferences

  • Press releaseBusiness Wire

    Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

  • Press releaseBusiness Wire

    Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European Countries

  • Press releaseBusiness Wire

    Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026

  • Press releaseBusiness Wire

    Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management

  • Press releaseBusiness Wire

    Stevanato Group Announces Results of Ordinary and Extraordinary Shareholders' Meeting

  • Press releaseBusiness Wire

    Stevanato Group Delivers 7% Revenue Growth (10% at Constant Currency) for the First Quarter of Fiscal 2026

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.